Newly developed retatrutide, a combined-action treatment targeting both GLP-1 and GIP receptors, is creating considerable interest within the healthcare community. Early clinical trials have revealed impressive reductions in overall mass and advancements in health markers for patients with excess weight . Scientists believe this novel approach … Read More